As part of our nation’s overall pandemic preparedness strategy, the US Department of Health and Human Services (HHS) set a preparedness goal of establishing and maintaining a stockpile of bulk vaccine antigen and adjuvants for influenza viruses with pandemic potential to vaccinate 26 million people immediately after a pandemic is declared.
The US Biomedical Advanced Research and Development Authority (BARDA) conducted a randomized, double-blinded Phase 2 clinical study with the oldest stockpiled influenza A(H5N1) antigen, stored over the previous 10–12 years administered with or without MF59® adjuvant, stored over the previous 2–7 years at the time of vaccination.
Using electronic medical record (EMR) data from the 2017-2018 flu season, researchers found that a cell-based influenza vaccine was 36.2% more effective than the standard egg-based version in preventing influenza-like illness.
This guidance is intended to provide advice to support planning an effective and consistent pandemic response by States and communities.
Recent research outlines how near-infrared spectroscopy could be used to make cell-culture-based flu vaccine manufacturing faster and more efficient.
Researchers showed that the risk of contracting the flu climbs about 16 percent for every 28 days after vaccination.
The first bout of flu may determine how a person fares during the next pandemic. That’s why scientists are trying to understand immunologic imprinting.
The double-layered vaccine made with peptides showed strong potential for combating influenza viruses, providing a promising approach for developing universal influenza vaccines.
The Phase 2 clinical trials will last 16 months, and will test the effectiveness of different dosages of the inactivated H7N9 virus vaccine candidate.
An effective universal vaccine would provide a huge leg up against an emerging influenza pandemic.